NCT02018250View on ClinicalTrials.gov

Study to Evaluate the Safety of a New Oxime, MMB4 DIMETHANESULFONATE (DMS)

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

March 17, 2012

Primary Completion Date

October 16, 2012

Study Completion Date

December 31, 2012

Conditions
Safety and Efficacy
Interventions
DRUG

MMB4 DMS

Subjects will be administered the drug product formulation at the assigned dosage of MMB4 DMS or placebo i.m. to the anterior thigh using a 5 mL syringe.

DRUG

Placebo

Subjects will be administered the drug product formulation at the assigned dosage of placebo i.m. to the anterior thigh using a 5 mL syringe. The placebo group in each cohort will receive the same injection volume and number of injections as the dose group in that cohort.

Trial Locations (1)

21201

SNBL Clinical Pharmacology Center, Inc., Baltimore

All Listed Sponsors
lead

U.S. Army Medical Research and Development Command

FED

NCT02018250 - Study to Evaluate the Safety of a New Oxime, MMB4 DIMETHANESULFONATE (DMS) | Biotech Hunter | Biotech Hunter